An observational study in Lung Diseases, sponsored by Aarhus University Hospital. Enrolling by invitation at 1 site in Denmark. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Aarhus University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Lung Diseases with a site in Denmark — 16 open to participants now, 20 under way, 8 of them phase 3. Lung Diseases · Denmark.
Among the 43 studies in Lung Diseases with a site in Denmark, this one is one of 5 that started in 2024, is one of 9 observational ones, reaches primary completion later than 13 of the 19 other live ones, and was the 36th registered.
1,159 studies on the registry are indexed under Lung Diseases; 181 are open to participants now.
Browse Lung Diseases studies →16 of the 43 studies in Lung Diseases with a site in Denmark are open now. Recruiting first, the newest first:
Gødstrup Hospital · Sites in Denmark
Ages 18+
Eli Lilly and Company · Sites in Denmark, United States, Argentina and 15 more countries
Ages 40–75
Grifols Therapeutics LLC · Sites in Denmark, United States, Germany and 6 more countries
Ages 18–80
Nuvalent Inc. · Sites in Denmark, United States, Argentina and 26 more countries
Ages 18+
Pfizer · Sites in Denmark, United States, Argentina and 15 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 138 Lung Diseases studies recruiting now, 75 (54%) set no upper age limit and 28 (20%) stop at 75 or younger; 15 take children under 18; 26 take healthy volunteers.
This study: 0 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 9 · Phase 3 14 · Phase 4 3
First in 2006; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is close to the median of 200 across 315 observational studies indexed under Lung Diseases.
Median enrollment 354 across the 33 interventional studies, 200 across the 9 observational. Of the 19 that completed or were terminated, 5 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 43 have an industry lead sponsor. The 10 most frequent:
Aarhus University Hospital is the lead sponsor of 298 studies on the registry; 80 are open to participants now.
Aarhus University Hospital has 1 study filed under Lung Diseases — fewer than ten, so there is no comparison to draw.
7 of the studies in Lung Diseases with a site in Denmark that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03683186Phase 3United TherapeuticsA Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | 2026-12 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT06119581Phase 3Eli Lilly and CompanyA Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | 2027-11 |
Add all 7 to your calendar (.ics) → With an account.
Among the 43 studies in Lung Diseases with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The INSPIRE CHILD-study is a clinical research project focused on understanding lung diseases in children. The study aims to explore how the presence of certain bacteria, immune responses, and inflammatory markers in the lungs are connected to different lung diseases in pediatric patients.
Background:
Lung diseases in children can have long-lasting effects on their health, not only during childhood but also as they grow into adults. However, the specific causes and mechanisms behind these diseases are not yet fully understood. The INSPIRE CHILD-study is designed to investigate whether children with various lung conditions have distinct differences in the types of bacteria, immune system activity, and inflammation in their lungs.
Hypothesis:
Different lung diseases in children are hypothesized to be associated with unique patterns of bacteria, immune responses, and inflammation in the lungs By studying these patterns, the investigators hope to gain new insights that could lead to better diagnostic tools and more personalized treatments for children suffering from lung diseases.
Children already scheduled to undergo bronchoscopy are included in the study. A small sample of fluid from the lungs is collected, and the sample is analyzed for bacteria, immune markers, and signs of inflammation. This research could pave the way for improved care and treatment for young patients with lung conditions.
Approximately 200 children/adolescents with lung disease undergo bronchoscopy yearly at Childrens Center for Pulmonary and Allergic diseases, Aarhus University Hospital. All patients are on clinical indication already scheduled for bronchoscopy and BAL. Participants are recruited from this group of patients if they comply with the inclusion/exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
No intervention
Cytokines
Legendplex assay for measuring cytokines in bronchoalveolar lavage fluid and plasma (e.g. IL-1-beta, IL-1RA, IL-2, IL-6, IL-8, IL-10, IL-17, IL-18, IL-33, IL-35, TGF-beta, TNF-alpha)
Time frame: Day 0 (Subsequent to study inclusion)
Immunophenotype
Using flow cytometry to investigate immune cells: e.g. Neutrophils, Eosinophils, Monocytes, NK-cells, B-cells, CD4+-T-cells, CD8+-T-cells
Time frame: Day 0 (Subsequent to study inclusion)
Lung microbiome
We seek to investigate whether it is feasible to map the microbiome, virome and mycobiome of the pediatric lung from BAL-fluid. The study will investigate and report findings of bioinformatics analysis.
Time frame: Day 0 (Subsequent to study inclusion)
Concentration range for selected interleukins in BAL-fluid
Time frame: Day 0 (Subsequent to study inclusion)
Lung disease association
Can we associate a specific profile of findings with a particular pediatric lung disease?
Time frame: Through study completion, an average of 2 year
Clinical symptoms
2 weeks prior to date of inclusion/bronchoscopy, the subjects medical history is reviewed for the following: Characterization of cough Respiratory distress Functional limitations (due to respiratory distress) (acc. to age) Fever (temperature above 38.0 C) Breath sounds Urgent need for medication
Time frame: 2 weeks prior to enrollment
Plan to share: Yes — Anonymized data that underlie the results reported in study articles (text, tables, figures, and appendices). The laws related to the handling of personal data will be followed and results are processed in accordance with the General Data Protection Regulation (GDPR) and the Danish Data Protection Act (Databeskyttelsesforordningen and Databeskyttelsesloven).
Supporting information: Study protocol, Informed consent form, Clinical study report
Time frame: After the study has been finalized.
Access criteria: Researchers who provide a methodologically sound proposal.
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Dec 2027, 44 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.